Positive Blood Culture Removal Time Significantly Decreases Processing Time
|
By LabMedica International staff writers Posted on 18 Feb 2015 |
Timely processing of blood cultures with positive results, including Gram staining and notification of clinicians, is a critical function of the clinical microbiology laboratory.
Although empiric administration of antibiotics is critical, targeted therapy based on actionable data from the clinical microbiology laboratory must be implemented as soon as the data are available as inadequate antimicrobial treatment of bloodstream infections is associated with significantly increased mortality and, in surviving patients, increased hospital length of stay.
Scientists at the Houston Methodist Hospital (TX, USA) performed a retrospective analysis of positive blood culture processing times. Data for specimens collected seven months before and seven months after an in-service meeting were retrieved and analyzed. In some instances, no organisms were seen on initial Gram stain after a positive alert. In those cases, the culture bottles were returned to the automated blood culture system BACTEC FX instrument (BD Diagnostics, Sparks, MD, USA) for further incubation. As the Epicenter software does not log the initial removal, the positive-to-removal (PR) time was erroneously prolonged, and these samples were excluded from the analysis.
Before the in-service meeting, the average PR time for 5,057 samples was 38 minutes. They discovered unexpectedly that only 51.8% (2,617 of 5,057) of the positive blood cultures were removed in less than 10 minutes. After the in-service meeting, for 5,293 samples, the average PR time improved to eight minutes, the aggregate time also improved, and 84.5% (4,470 of 5,293) of the positive blood cultures were removed in less than 10 minutes. These improvements reduced the time to telephone notification of the Gram stain results to a caregiver by 46.7% (from 105 minutes to 56 minutes).
The authors concluded improvement of sepsis outcomes and costs requires rapid generation of actionable data from the clinical microbiology laboratory. Vigilant monitoring of parameters such as the PR time and meticulous identification of barriers to rapid pathogen identification has the potential to continue to decrease pathogen reporting time, decrease health care costs, and decrease morbidity and mortality associated with bloodstream infections. The study was published in the February 2015 issue of the Archives of Pathology & Laboratory Medicine.
Related Links:
Houston Methodist Hospital
BD Diagnostics
Although empiric administration of antibiotics is critical, targeted therapy based on actionable data from the clinical microbiology laboratory must be implemented as soon as the data are available as inadequate antimicrobial treatment of bloodstream infections is associated with significantly increased mortality and, in surviving patients, increased hospital length of stay.
Scientists at the Houston Methodist Hospital (TX, USA) performed a retrospective analysis of positive blood culture processing times. Data for specimens collected seven months before and seven months after an in-service meeting were retrieved and analyzed. In some instances, no organisms were seen on initial Gram stain after a positive alert. In those cases, the culture bottles were returned to the automated blood culture system BACTEC FX instrument (BD Diagnostics, Sparks, MD, USA) for further incubation. As the Epicenter software does not log the initial removal, the positive-to-removal (PR) time was erroneously prolonged, and these samples were excluded from the analysis.
Before the in-service meeting, the average PR time for 5,057 samples was 38 minutes. They discovered unexpectedly that only 51.8% (2,617 of 5,057) of the positive blood cultures were removed in less than 10 minutes. After the in-service meeting, for 5,293 samples, the average PR time improved to eight minutes, the aggregate time also improved, and 84.5% (4,470 of 5,293) of the positive blood cultures were removed in less than 10 minutes. These improvements reduced the time to telephone notification of the Gram stain results to a caregiver by 46.7% (from 105 minutes to 56 minutes).
The authors concluded improvement of sepsis outcomes and costs requires rapid generation of actionable data from the clinical microbiology laboratory. Vigilant monitoring of parameters such as the PR time and meticulous identification of barriers to rapid pathogen identification has the potential to continue to decrease pathogen reporting time, decrease health care costs, and decrease morbidity and mortality associated with bloodstream infections. The study was published in the February 2015 issue of the Archives of Pathology & Laboratory Medicine.
Related Links:
Houston Methodist Hospital
BD Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Channels
Clinical Chemistry
view channel
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read more
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read moreMolecular Diagnostics
view channel
Group A Strep Molecular Test Delivers Definitive Results at POC in 15 Minutes
Strep throat is a bacterial infection caused by Group A Streptococcus (GAS). It is a leading bacterial cause of acute pharyngitis, particularly in children and adolescents, and one of the most common reasons... Read more
Rapid Molecular Test Identifies Sepsis Patients Most Likely to Have Positive Blood Cultures
Sepsis is caused by a patient’s overwhelming immune response to an infection. If undetected or left untreated, sepsis leads to tissue damage, organ failure, permanent disability, and often death.... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
High-Resolution Cancer Virus Imaging Uncovers Potential Therapeutic Targets
Human T-cell leukemia virus (HTLV) is a retrovirus that causes adult T-cell leukemia/lymphoma, a serious blood cancer with no approved treatment. Although related to HIV, HTLV remains less understood at... Read more
AI Tool Helps See How Cells Work Together Inside Diseased Tissue
Microscopes have long been central to diagnosing disease by allowing doctors to examine stained tissue samples. However, modern medical research now generates vast amounts of additional data, including... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read moreNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more








